You are here: Industry Insights > LDL-C

News List

FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C) Drugs
December 27, 2021
Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol...
AstraZeneca Initiates Study of Antisense Med Targeting PCSK9 to Lower LDL-Cholesterol americanpharmaceuticalreview
December 17, 2020
Ionis Pharmaceuticals announced that biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by ...
Novartis analysis shows inclisiran lowers LDL-C with high consistency expresspharma
August 31, 2020
The analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran).
FDA approves Esperion’s non-statin LDL-C lowering drug pharmaceutical-technology
March 03, 2020
Esperion has announced the US Food and Drug Administration (FDA) has approved Nexlizet (bempedoic acid and ezetimibe).
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering b3cnewswire
August 01, 2019
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’)announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study...
Higher LDL-C Levels Linked to Early-Onset Alzheimer Disease drugs
June 03, 2019
Higher LDL-C Levels Linked to Early-Onset Alzheimer Disease.
Esperion’s cholesterol drug cuts LDL-C in phase 3 fiercebiotech
August 28, 2018
The study also linked the combination to a reduction in high-sensitivity C-reactive protein.
Landmark outcomes study shows that Repatha decreases LDL-C to unprecedented low levels cphi-online
March 20, 2017
Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha.
Repatha demonstrates reduced need for apheresis in patients with high LDL-C in study cphi-online
March 15, 2017
Data suggest an alternative option for patients.